The Gene And Cell Therapies Targeting Cns Disorders Market is estimated to be valued at US$ 8.2 Bn in 2023 and is expected to exhibit a CAGR of 30% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Gene and cell therapies targeting CNS disorders involve the use of gene therapy or stem cell therapy for treating various neurological conditions like Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, etc. These therapies work by delivering gene(s) or cells to replace dysfunctional or missing genes responsible for causing the disease. Gene therapy offers the potential of a one-time, curative treatment for several conditions for which there were previously no options.

Market key trends:
The key trend driving the growth of gene and cell therapies targeting CNS disorders market is the increasing adoption of gene therapy for treating neurodegenerative diseases. Gene therapy provides a promising potential as it allows researchers to deliver novel genes directly into the brain cells to compensate for malfunctioning or absent genes. Moreover, gene therapy enables sustained levels of therapeutic protein production at the site of pathology within the CNS itself. Another major trend is the rising research activities for developing advanced cell-based therapies for treating chronic neurological conditions. According to ClinicalTrials.gov database, currently there are over 200 active clinical trials focused on evaluating gene and cell therapies for various CNS disorders. In addition, increasing collaborations between biotech and pharmaceutical companies for advancing neuroscience research further support market growth over the forecast period.

Porter's Analysis

Threat of new entrants: Low barriers to entry due to ongoing rapid technological advancements and popularity of gene and cell therapies targeting CNS disorders.

Bargaining power of buyers: Moderate as major customers are hospitals and research institutes. Continuous product innovation and new pipeline drugs enhance the value proposition.

Bargaining power of suppliers: Moderate as key ingredients and inputs are proprietary in nature with limited substitutes available. Suppliers have pricing power due to high R&D investments.

Threat of new substitutes: Low as gene and cell therapies offer highly effective and customized treatment solutions with minimal side effects compared to other CNS disorder therapies.

Competitive rivalry: High due to presence of numerous global and local players offering differentiated products and solutions. Fierce competition to gain first mover advantage.

SWOT Analysis

Strengths: Large patient pool, rising healthcare spending, advancing genetic engineering technologies.

Weaknesses: High R&D costs, lengthy approval timelines, manufacturing complexities.

Opportunities: Promising clinical trial results, collaborations with pharma companies, growing biotech sector.

Threats: Stringent regulations, reimbursement issues, manufacturing quality concerns.

Key Takeaways

The Global Gene And Cell Therapies Targeting Cns Disorders Market Size is expected to witness high growth at a CAGR of 30% over the forecast period due to increasing prevalence of CNS disorders like Parkinson’s disease, spinal cord injuries, multiple sclerosis. The market size is projected to reach US$ 141.8 Bn by 2030 from US$ 8.2 Bn in 2023.

Regional analysis: North America dominated the global market in 2023 and is expected to maintain its leading position throughout the forecast period. This is attributed to advanced healthcare infrastructure, rising awareness about novel treatments, and presence of key players in the region. The Asia Pacific market is anticipated to exhibit fastest growth CAGR over 2023-2030 owing to rising healthcare spending, large patient population, and growing focus of international players in the region.

Key players: Key players operating in the gene and cell therapies targeting CNS disorders market are Novartis, Brainstorm Cell Therapeutics, Helminth, Core stem, Q therapeutics, Rapa Therapeutics, Neuroblast, Osteocyte, Ferrer International, Neuralstem, Semeia Cell Technologies, Labella Gene Therapeutics, Sangamon Therapeutics, Hoffmann-La Roche, Longeron, Soi Gene Therapies, Prevail Therapeutics (Eli Lilly and Company), Aerogeneration, Brain Neurotherapy Bio (Ask Bio), Unique Biopharma, Neurogenic Inc., Passage Bio, AXOVANT SCIENCES GMBH, Meira Tx Limited, Asclepios Bi

For More Insights, Read: https://www.newswirestats.com/gene-and-cell-therapies-targeting-cns-disorders-market-demand-growth-and-regional-outlook-by-2030/